Filing summary
Identity mismatch: The supplied filing is for Spatializer Audio Laboratories, Inc. (Form 10-Q, quarter ended June 30, 2012), not Enveric Biosciences, Inc. The filing also identifies Spatializer as a shell company. This summary reflects the filing text provided.
Business context and reporting period
The report covers the three and six months ended June 30, 2012, with comparisons to the same periods in 2011. Spatializer says it ceased commercial operations in 2006, expects no significant operations until a merger, acquisition, business combination, or other appropriate financial transaction, and is seeking such opportunities. The interim financial statements are unaudited.
Financial performance and liquidity
| Metric | Q2 2012 | Q2 2011 | Six months 2012 | Six months 2011 |
|---|---|---|---|---|
| Revenue | $0 | $0 | Not separately stated | Not separately stated |
| Operating expenses | $4,082 | $3,632 | $8,127 | $14,716 |
| Net loss | $4,082 | $3,632 | $8,127 | $14,716 |
| Loss per share | $(0.00) | $(0.00) | $(0.00) | $(0.00) |
At June 30, 2012, cash and cash equivalents were $2,200, down from $18,231 at December 31, 2011. Total current assets were $6,419 and current liabilities were $9,991, resulting in negative working capital of $3,572; at year-end 2011, working capital was positive $4,555. Stockholders’ equity was a deficit of $3,572. The balance sheet lists accounts payable and accrued liabilities, but no other debt balance.
For the first half of 2012, net cash used in operating activities was $16,031, compared with $21,878 in the first half of 2011. Cash declined by $16,031 during the 2012 period. The filing reports no interest or income tax payments.
Changes, outlook, and risks
- Second-quarter net loss increased to $4,082 from $3,632 year over year, while six-month net loss improved to $8,127 from $14,716, primarily alongside lower reported operating expenses.
- Management said current cash reserves were insufficient to meet operating obligations for more than three to six months without additional capital and that the company had no current source of future cash flow. It believed liquidity could be maintained at a consistent level in the short term.
- The company’s significant operating losses and circumstances raise substantial doubt about its ability to continue as a going concern. The financial statements include no adjustments for the outcome of that uncertainty.
- In July 2012, President Jay Gottlieb loaned the company $5,000 interest-free to help fund operating expenses. The filing reports no other material subsequent events requiring disclosure.
- Federal net operating loss carryforwards were approximately $9.5 million, available through 2031, subject to an approximately $1 million annual limitation and possible further ownership-change limitations.
- The filing says there were no legal proceedings expected to have a material adverse effect, while noting litigation uncertainty. It also flags possible stock-market illiquidity and volatility. Management concluded disclosure controls were effective and reported no material quarterly change in internal control over financial reporting.
Important facts for investors to verify
- Confirm the intended issuer: the supplied document is Spatializer’s 2012 filing, not an Enveric Biosciences filing.
- Verify the company’s ability to fund operations beyond the stated three-to-six-month period, including the effect and terms of the July officer loan and any subsequent financing.
- Assess the going-concern uncertainty, lack of operating revenue, and status of any proposed merger or business combination.
- Review the filing’s risk factors and ownership-related limitations on use of tax loss carryforwards.